Premium
Photo‐damage in Northern European renal transplant recipients is associated with use of calcium channel blockers
Author(s) -
Cooper S. M.,
Wojnarowska F.
Publication year - 2003
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1046/j.1365-2230.2003.01408.x
Subject(s) - medicine , telangiectasia , amlodipine , calcium channel blocker , erythema , calcium channel , nifedipine , dermatology , population , calcium , blood pressure , environmental health
Summary Photo‐damage of the head and neck was assessed, by visual inspection, in 82 Northern European renal transplant recipients attending a dermatology clinic. Photo‐damage was graded as absent, mild, moderate and severe and the presence or absence of skin telangiectasia, solar elastosis, erythema and pigmentation was assessed. The duration and type of immunosuppressant and calcium channel blocker medication was recorded. Ninety percent had photo‐damaged skin with 41 (50%) having mild photo‐damage, 20 (24%) moderate photo‐damage and 13 (16%) severe photo‐damage. Sixty‐two (76%) had pigmentation, 43 (52%) telangiectasia, 65 (79%) papular changes and 51 (65%) erythema. Fifty‐three patients (65%) had received a calcium channel blocker (49 nifedipine, four amlodipine). The grade of photo‐damage was strongly associated with use of calcium channel blockers ( P = 0.001) as was the presence of telangiectasia ( P = 0.001) and solar elastosis ( P = 0.04). Photo‐damage is frequent in this population of renal transplant patients. Telangiectasia in association with calcium channel blockers has been reported rarely but appears to be common in the transplant population.